BTK C481S-Mediated Resistance to Ibrutinib in ... - CLL Support

CLL Support

23,089 members39,652 posts

BTK C481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia

bkoffman profile image
bkoffmanCLL CURE Hero
5 Replies

It gets kinda technical but this is some great research on ibrutinib resistance by Dr. Woyach.

ascopubs.org/doi/pdf/10.120... will give you access to the whole article

If you want just a very clear and helpful summary, Dr. Wiestner provides it here:

ascopubs.org/jco/site/podca...

A few highlights:

For treatment naive patients even those with del. 17p, have a very low progression rate of 1.9%

There are blood markers that can predict relapse before it occurs.

Most Richter’s Transformation (RT) occurs early in the first 2 years, while CLL progression is rare in the first year, but increases over time.

Prognosis for RT remains poor, but for CLL progression after ibrutinib it is getting better.

Stay strong.

We are all in this together.

Brian

cllsociety.org

bkoffman.blogspot.com

Written by
bkoffman profile image
bkoffman
CLL CURE Hero
To view profiles and participate in discussions please or .
Read more about...
5 Replies
Ernest2 profile image
Ernest2

Interested about the aspect regarding the Ibrutinib metabolism as we get older. Good to have something to look forward to that improves with age I guess. Dosage is such a tricky subject.

Ernest.

vepiskop profile image
vepiskop

Dear Brian,

This is indeed very useful.

Many thanks

Vasso

Jm954 profile image
Jm954Administrator

I didn't feel very optimistic after reading this, as patients who experienced relapse on Ibrutinib often had rapid progression and poor outcomes. I realise that this was a pre-treated group but progression was as high as 44% after 4 years for those age less than 65 years which is very worrying (but reassuringly low at 1.9% for those age 65+).

If only we could all get access to clinical-grade mutation monitoring and then a therapeutic intervention in the 9 months between mutation identification and clinical relapse. Not even sure who does this type of testing in UK or if it's part of the scientific aspect of the FLAIR study.

Berrytog profile image
Berrytog

Brian

I wrote to you about Ibrutinib not long after you started to gain advice as a treatment naive patient 13 Del. in need of treatment after six years of W & W and now with AIHA, white count over 250 and very low platelets and red blood.

Now in my early seventies, I find the article most hopeful as since starting on Ibrutinib, three and a half years ago, I have had no symptoms, save for the brittle finger nails that now seem to be more or less resolved. I went to hospital today as I now do every two months, always touching wood for good results, and have to report that as per my last three visits all my blood levels were well within the normal ranges. (Hb 159, WBC 8, Lymphocytes 3.8, Neutrophils 3.6 and platelets163.

Feeling twenty years younger I am for ever grateful for your guidance and hope that my results continue to stay good.

Berrytog.

bkoffman profile image
bkoffmanCLL CURE Hero

I am so happy for you and glad that you shared your good news.

Not what you're looking for?

You may also like...

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: Update on The CLARITY Study

Published on line July 11, 2019, Accepted by JCO May 31 2019 Dr P Hillmen We have some members who...

Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies

I have checked but apologies if this has been posted before. Published online June 13, 2019. Key...

Dr. John Allan - Chronic Lymphocytic Leukemia (CLL) Patients @Undetectable Measurable Residual Disease (MRD) after Ibrutinib Plus Venetoclax

ASH 2022: Dr. John Allan on Outcomes for Chronic Lymphocytic Leukemia (CLL) Patients with...

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease

From the New England Journal of Medicine 10th December 2023 "The CLL treatment landscape has...

Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia ( CLL ) - Pseudo Richters

Several of us have reported our CLL symptoms have come roaring back after discontinuing...